Top 5 Stocks to Buy Now
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SOPH Stock Alerts

SOPHiA GENETICS (SOPH) Competitors

SOPHiA GENETICS logo
$5.23 -0.11 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$5.24 +0.00 (+0.10%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SOPH vs. INBX, PURR, MAZE, PAHC, and MRVI

Should you buy SOPHiA GENETICS stock or one of its competitors? MarketBeat compares SOPHiA GENETICS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SOPHiA GENETICS include Inhibrx Biosciences (INBX), Hyperliquid Strategies (PURR), Maze Therapeutics (MAZE), Phibro Animal Health (PAHC), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does SOPHiA GENETICS compare to Inhibrx Biosciences?

SOPHiA GENETICS (NASDAQ:SOPH) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SOPHiA GENETICS has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M5.68-$79M-$0.52N/A
Inhibrx Biosciences$1.30M1,048.45-$140.05M-$8.39N/A

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.31, suggesting that its stock price is 231% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Inhibrx Biosciences N/A -563.90%-72.32%

SOPHiA GENETICS presently has a consensus price target of $7.50, suggesting a potential upside of 43.40%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 61.45%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Inhibrx Biosciences
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

In the previous week, SOPHiA GENETICS had 9 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 0 mentions for Inhibrx Biosciences. SOPHiA GENETICS's average media sentiment score of 0.09 beat Inhibrx Biosciences' score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company Overall Sentiment
SOPHiA GENETICS Neutral
Inhibrx Biosciences Neutral

Summary

SOPHiA GENETICS beats Inhibrx Biosciences on 9 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Hyperliquid Strategies?

SOPHiA GENETICS (NASDAQ:SOPH) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

In the previous week, SOPHiA GENETICS had 8 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 1 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.89 beat SOPHiA GENETICS's score of 0.09 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company Overall Sentiment
SOPHiA GENETICS Neutral
Hyperliquid Strategies Positive

Hyperliquid Strategies has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M5.68-$79M-$0.52N/A
Hyperliquid Strategies$1M1,175.82-$16.01M-$7.37N/A

SOPHiA GENETICS currently has a consensus target price of $7.50, suggesting a potential upside of 43.40%. Hyperliquid Strategies has a consensus target price of $9.25, suggesting a potential upside of 13.64%. Given SOPHiA GENETICS's higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Hyperliquid Strategies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Hyperliquid Strategies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hyperliquid Strategies has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Hyperliquid Strategies' return on equity of -56.04% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Hyperliquid Strategies N/A -56.04%-52.22%

Summary

Hyperliquid Strategies beats SOPHiA GENETICS on 9 of the 15 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

31.6% of SOPHiA GENETICS shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Maze Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 149.91%. SOPHiA GENETICS has a consensus price target of $7.50, suggesting a potential upside of 43.40%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maze Therapeutics is more favorable than SOPHiA GENETICS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Maze Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

SOPHiA GENETICS has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M8.73-$131.12M-$2.53N/A
SOPHiA GENETICS$77.27M5.68-$79M-$0.52N/A

Maze Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Maze Therapeutics' return on equity of -36.62% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -36.62% -31.78%
SOPHiA GENETICS -44.48%-62.74%-21.85%

In the previous week, SOPHiA GENETICS had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.67 beat SOPHiA GENETICS's score of 0.09 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
SOPHiA GENETICS
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Maze Therapeutics beats SOPHiA GENETICS on 11 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Phibro Animal Health?

SOPHiA GENETICS (NASDAQ:SOPH) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to SOPHiA GENETICS's net margin of -44.48%. Phibro Animal Health's return on equity of 37.14% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Phibro Animal Health 6.35%37.14%8.57%

In the previous week, SOPHiA GENETICS had 6 more articles in the media than Phibro Animal Health. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 3 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.31 beat SOPHiA GENETICS's score of 0.09 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Phibro Animal Health
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

SOPHiA GENETICS currently has a consensus target price of $7.50, suggesting a potential upside of 43.40%. Phibro Animal Health has a consensus target price of $42.50, suggesting a potential upside of 39.21%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Phibro Animal Health
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Phibro Animal Health has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M5.68-$79M-$0.52N/A
Phibro Animal Health$1.30B0.96$48.26M$2.3313.10

Summary

Phibro Animal Health beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Maravai LifeSciences?

SOPHiA GENETICS (NASDAQ:SOPH) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

SOPHiA GENETICS presently has a consensus price target of $7.50, suggesting a potential upside of 43.40%. Maravai LifeSciences has a consensus price target of $5.50, suggesting a potential upside of 2.42%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Maravai LifeSciences
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

SOPHiA GENETICS has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

SOPHiA GENETICS has a net margin of -44.48% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat SOPHiA GENETICS's return on equity.

Company Net Margins Return on Equity Return on Assets
SOPHiA GENETICS-44.48% -62.74% -21.85%
Maravai LifeSciences -51.07%-17.87%-9.08%

In the previous week, SOPHiA GENETICS had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat SOPHiA GENETICS's score of 0.09 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOPHiA GENETICS
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maravai LifeSciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

SOPHiA GENETICS has higher earnings, but lower revenue than Maravai LifeSciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOPHiA GENETICS$77.27M5.68-$79M-$0.52N/A
Maravai LifeSciences$185.74M7.46-$130.77M-$0.71N/A

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SOPHiA GENETICS and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SOPH vs. The Competition

Export
MetricSOPHiA GENETICSMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$448M$1.54B$6.45B$12.39B
Dividend YieldN/AN/A2.69%5.83%
P/E Ratio-10.0650.6221.0722.20
Price / Sales5.687.34530.36110.15
Price / CashN/A23.5044.8254.51
Price / Book7.585.1610.796.50
Net Income-$79M-$54.76M$3.56B$336.88M
7 Day Performance6.09%-1.75%1.67%-0.22%
1 Month Performance7.17%-3.64%0.43%0.77%
1 Year Performance71.48%-1.78%32.84%31.57%

SOPHiA GENETICS Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SOPH
SOPHiA GENETICS
2.4917 of 5 stars		$5.23
-2.1%		$7.50
+43.4%		+75.7%$448M$77.27MN/A520
INBX
Inhibrx Biosciences
2.0124 of 5 stars		$93.11
-0.4%		$150.00
+61.1%		+524.9%$1.37B$1.30MN/A166
PURR
Hyperliquid Strategies
2.5943 of 5 stars		$10.04
+7.5%		$9.25
-7.9%		N/A$1.35B$1MN/AN/A
MAZE
Maze Therapeutics
3.1638 of 5 stars		$23.86
-1.7%		$66.00
+176.6%		+128.7%$1.34B$167.50MN/A121
PAHC
Phibro Animal Health
4.8601 of 5 stars		$31.87
-1.3%		$42.50
+33.4%		+30.1%$1.31B$1.50B13.682,475

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel